Akero Therapeutics Inc represents a commitment to advancing transformative treatments for serious metabolic diseases. The company's corporate philosophy is centered around innovation, collaboration, and dedication to improving patient outcomes. Akero Therapeutics Inc aims to develop and commercialize therapies that address the underlying causes of metabolic disease, such as non-alcoholic steatohepatitis (NASH) and other related disorders. With a focus on scientific excellence, Akero Therapeutics Inc strives to deliver groundbreaking solutions that positively impact the lives of patients worldwide.

Akero Therapeutics Inc is primarily present in the United States.

Akero Therapeutics Inc, a renowned pharmaceutical company, has accomplished several significant milestones. One notable achievement is the successful completion of its Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). As part of this trial, Akero Therapeutics Inc demonstrated positive outcomes by reducing liver fat and fibrosis in patients. Additionally, the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug AKR-001, highlighting its potential to address unmet medical needs in NASH treatment. These achievements portray Akero Therapeutics Inc as a promising player in the pharmaceutical industry, dedicated to advancing therapies for liver diseases.

Akero Therapeutics Inc., headquartered in San Francisco, California, is a clinical-stage biotechnology company focused on developing transformative treatments for serious metabolic diseases. Established in 2018, Akero aims to improve the lives of patients suffering from conditions such as non-alcoholic steatohepatitis (NASH) and other systemic metabolic disorders. The company's innovative approach involves utilizing the power of endocrine hormone FGF21 to address the underlying causes of these diseases. With a dedicated team of scientific experts and strong financial backing, Akero is committed to advancing novel therapies and bringing hope to patients worldwide.

Some of the main competitors of Akero Therapeutics Inc in the market include companies like Madrigal Pharmaceuticals, Viking Therapeutics, and Intercept Pharmaceuticals.

Akero Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Akero Therapeutics Inc is focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases. The company aims to provide innovative solutions through their proprietary discovery platform and strategic partnerships. Akero Therapeutics Inc focuses on addressing unmet medical needs in diseases such as non-alcoholic steatohepatitis (NASH) and other metabolic disorders. By utilizing their expertise in biology, chemistry, and clinical development, Akero Therapeutics Inc aims to deliver breakthrough therapies that improve the lives of patients worldwide.

Akero Therapeutics에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Akero Therapeutics에 대한 현재 KUV는 계산할 수 없습니다.

Akero Therapeutics에 대한 AlleAktien 품질 점수는 2/10입니다.

Akero Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

예상되는 Akero Therapeutics 이익은 -336.95 백만 USD입니다.

The company Akero Therapeutics Inc develops biopharmaceutical products for the treatment of metabolic diseases. The company focuses mainly on the research and development of drugs for the treatment of non-alcoholic fatty liver disease (NAFLD), one of the most common metabolic diseases worldwide. The strategy of Akero Therapeutics is to utilize the activation of the G-protein-coupled receptor 119 (GPR119) to increase insulin release and regulate the behavior of liver cells and fat oxidation in the liver. One of the key products of Akero Therapeutics is AKR-001, a fibroblast growth factor 21 (FGF21) modified by fusion of Fc and aprotinin, which increases GPR119 activation and regulates the behavior of liver cells and fat oxidation. Akero Therapeutics also utilizes a proprietary technology platform to identify biomarkers to optimize patient selection and facilitate the development of products in the pipeline. This is intended to expedite the approval of drugs and improve their efficacy. In addition to discovering new drugs, Akero Therapeutics collaborates closely with health authorities, academics, and patient organizations to raise awareness of metabolic diseases and support patients in the early detection and treatment of NAFLD. The business activities of Akero Therapeutics also include a partnership with Japan Tobacco Inc, which provides the company with financial resources to advance drug development. The company also actively solicits investors to invest in the research and development of new products. In summary, Akero Therapeutics is an innovative biopharmaceutical company focused on the research and development of drugs for the treatment of metabolic diseases. Through the utilization of a proprietary technology platform and partnerships with global health authorities, the company aims to bring to market drugs that meet the needs of patients and improve their lives.

Akero Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Akero Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Akero Therapeutics의 ISIN은 US00973Y1082입니다.

Akero Therapeutics의 WKN은 A2PLNP입니다.

Akero Therapeutics의 티커는 AKRO입니다.

지난 12개월 동안 Akero Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Akero Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Akero Therapeutics의 현재 배당 수익률은 입니다.

Akero Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Akero Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Akero Therapeutics은 '건강' 섹터에 속합니다.

Akero Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Akero Therapeutics는 0 USD를 배당금으로 지급했습니다.

Akero Therapeutics의 배당금은 USD에 지급됩니다.